1.93
-0.04 (-2.03%)
| Previous Close | 1.97 |
| Open | 2.00 |
| Volume | 38,346 |
| Avg. Volume (3M) | 323,388 |
| Market Cap | 32,647,108 |
| Price / Book | 2.90 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Diluted EPS (TTM) | -2.36 |
| Current Ratio (MRQ) | 0.150 |
| Operating Cash Flow (TTM) | -10.64 M |
| Levered Free Cash Flow (TTM) | -3.99 M |
| Return on Assets (TTM) | -224.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | NRX Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
|
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 17.08% |
| % Held by Institutions | 6.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| One Wealth Management Investment & Advisory Services, Llc | 31 Dec 2024 | 15,041 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (D. Boral Capital, 1,506.22%) | Buy |
| Median | 19.00 (884.46%) | |
| Low | 18.00 (BTIG, 832.64%) | Buy |
| Average | 22.67 (1,074.61%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 02 Apr 2025 | 18.00 (832.64%) | Buy | 2.01 |
| D. Boral Capital | 31 Mar 2025 | 31.00 (1,506.22%) | Buy | 2.05 |
| 24 Mar 2025 | 31.00 (1,506.22%) | Buy | 2.07 | |
| HC Wainwright & Co. | 20 Mar 2025 | 19.00 (884.46%) | Buy | 2.07 |
| 14 Mar 2025 | 19.00 (884.46%) | Buy | 2.35 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |